Global Left Atrial Appendage (LAA) Closure Market 2016-2020
Market outlook of the left atrial appendage closure market
The left atrial appendage (LAA) is a small ear-shaped sac in the muscle wall of the top left chamber of the heart that controls the electrical impulses during atrial fibrillation. LAA closure device is an interventional device used to prevent stroke, reduce the risk of secondary stroke and emboli because of atrial fibrillation. The global left atrial appendage closure market is expected to grow at a massive CAGR of over 28% during the forecast period.
Numerous factors drive the left atrial appendage closure market, but one of the main factors is the significant increase in the incidences of stroke. It is estimated that around 15 million people suffer a stroke every year across the globe. With the rise in the aging population, excessive smoking, average hypertension, and cholesterol levels, the number of atrial fibrillation cases is also increasing globally.
Segmentation by product and analysis of - epicardial LAA closure and endocardial LAA closure
The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -
Technavio Announces the Publication of its Research Report – Global Left Atrial Appendage Closure Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Left Atrial Appendage Closure Market: AtriCure, Boston Scientific, St. Jude and Coherex Medical
Other Prominent Vendors in the market are: Lifetech Scientific, SentreHEART, and Occlutech.
Commenting on the report, an analyst from Technavio’s team said: “One of the major trends is the increasing focus on clinical trials by vendors for new product launches in the untapped market such as the US and APAC. This factor propels the growth of the market during the forecast period. The increase in awareness programs and significant growth opportunity in the US are also expected to boost market growth in the future.”
According to the report, one of the major growth factors is a significant increase in the incidences of stroke. It is estimated that 15 million people worldwide suffer a stroke each year. With the rise in the aging population, excessive smoking, average hypertension, and cholesterol levels, the number of atrial fibrillation cases is also increasing across the globe.
Further, the report states that one of the major challenges is the complicated LAA closure implantation procedure that requires experienced surgeons. Also, post implantation, timely procedural follow up and medical treatment are needed. This factor restrains the adoption of LAA closure devices.
AtriCure, Boston Scientific, St. Jude, Coherex Medical, Lifetech Scientific, SentreHEART, Occlutech.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook